Twelve-Month Clinical and Quality-of-Life Outcomes in the Interventional Management of Stroke III Trial
Yuko Y Palesch, Sharon D Yeatts, Thomas A Tomsick, Lydia D Foster, Andrew M Demchuk, Pooja Khatri, Michael D Hill, Edward C Jauch, Tudor G Jovin, Bernard Yan, Ruediger von Kummer, Carlos A Molina, Mayank Goyal, Wouter J Schonewille, Mikael Mazighi, Stefan T Engelter, Craig Anderson, Judith Spilker, Janice Carrozzella, Karla J Ryckborst Show all
Stroke | LIPPINCOTT WILLIAMS & WILKINS | Published : 2015
BACKGROUND AND PURPOSE: Randomized trials have indicated a benefit for endovascular therapy in appropriately selected stroke patients at 3 months, but data regarding outcomes at 12 months are currently lacking. METHODS: We compared functional and quality-of-life outcomes at 12 months overall and by stroke severity in stroke patients treated with intravenous tissue-type plasminogen activator followed by endovascular treatment as compared with intravenous tissue-type plasminogen activator alone in the Interventional Management of Stroke III Trial. The key outcome measures were a modified Rankin Scale score ≤2 (functional independence) and the Euro-QoL EQ-5D, a health-related quality-of-life me..View full abstract
Awarded by National Institute of Health/NINDS
Awarded by NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
Awarded by Alberta Innovates
National Institute of Health/NINDS Grant Numbers: University of Cincinnati U01NS052220 and Medical University of South Carolina U01NS054630 and U01NS077304. Genentech Inc. supplied study drug used for intra-arterial tPA in the Endovascular group. EKOS Corp., Concentric Inc., Cordis Neurovascular, Inc. supplied study catheters during Protocol Versions 1-3. In the United States, IMS III investigator meeting support was provided in part by Genentech Inc, EKOS Corp., and Concentric Inc. In Europe, IMS III investigator meeting support was provided in part by Boehringer Ingelheim. Y.Y. Palesch, S.D. Yeatts, L.D. Foster, A. Simpson, K.N. Simpson, J.P. Broderick were responsible for the analyses used in this article. Y.Y. Palesch and J.P. Broderick had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.